Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years

Thanyawee Puthanakit, Li Min Huang, Cheng Hsun Chiu, Ren Bin Tang, Tino F. Schwarz, Susanna Esposito, Louise Frenette, Carlo Giaquinto, Shelly McNeil, Paul Rheault, Paolo Durando, Michael Horn, Maximilian Klar, Sylviane Poncelet, Stéphanie De Simoni, Damien Friel, Benoit De Muynck, Pemmaraju V. Suryakiran, Marjan Hezareh, Dominique DescampsFlorence Thomas, Frank Struyf

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)
Original languageEnglish
Pages (from-to)525-536
Number of pages12
JournalJournal of Infectious Diseases
Volume214
Issue number4
DOIs
Publication statusPublished - Aug 15 2016

ASJC Scopus Subject Areas

  • Infectious Diseases
  • Immunology and Allergy

Keywords

  • 2-dose schedule
  • AS04
  • Adjuvant System containing 50 ?g 3-O-desacyl-4?-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 ?g Al3+)
  • CMI
  • Cell-mediated immunity
  • Cervical cancer
  • GMT
  • Geometric mean antibody titer
  • HPV
  • Human papillomavirus
  • IgG
  • Immunogenicity

Fingerprint

Dive into the research topics of 'Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years'. Together they form a unique fingerprint.

Cite this